

**(12) PATENT**  
**(19) AUSTRALIAN PATENT OFFICE**

**(11)** Application No. **AU 199916962 B2**  
**(10)** Patent No. **758858**

(54) Title  
**Biodegradable intra vaginal devices**

(51)<sup>7</sup> International Patent Classification(s)  
**A61D 019/00                      A61K 047/06**  
**A61F 006/08                      A61K 047/30**  
**A61K 009/02                      A61M 031/00**

(21) Application No: **199916962**

(22) Application Date: **1998.11.23**

(87) WIPO No: **WO99/26556**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>329229</b>	<b>1997.11.21</b>	<b>NZ</b>
<b>330595</b>	<b>1998.06.05</b>	<b>NZ</b>
<b>330596</b>	<b>1998.06.05</b>	<b>NZ</b>

(43) Publication Date : **1999.06.15**

(43) Publication Journal Date : **1999.08.12**

(44) Accepted Journal Date : **2003.04.03**

(71) Applicant(s)  
**InterAg**

(72) Inventor(s)  
**Craig Robert Bunt; Michael John Rathbone; Shane Burggraaf; Vaughan Grant Woodward; Colin Roger Ogle**

(74) Agent/Attorney  
**A J PARK and SON,PO Box 565,AUCKLAND,New Zealand**

(56) Related Art  
**WO 98/53758**  
**WO 93/24154**  
**US 5116619**




PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61D 19/00, A61F 6/08, A61K 9/02, 47/06, 47/30, A61M 31/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/26556</b>
			(43) International Publication Date: <b>3 June 1999 (03.06.99)</b>
(21) International Application Number: <b>PCT/NZ98/00169</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>23 November 1998 (23.11.98)</b>			
(30) Priority Data: 329229                      21 November 1997 (21.11.97)    NZ 330595                      5 June 1998 (05.06.98)                      NZ 330596                      5 June 1998 (05.06.98)                      NZ			
<b>INTERAG</b> (71) Applicant (for all designated States except US): <del>DEC INTERNATIONAL NZ LIMITED</del> [NZ/NZ]; 558 Te Rapa Road, Hamilton (NZ).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BUNT, Craig, Robert [NZ/NZ]; <del>81A Karaka Street</del> , Hamilton (NZ). RATHBONE, Michael, John [GB/NZ]; 11 Walsh Street, Forest Lake, Hamilton (NZ). BURGGRAAF, Shane [GB/NZ]; <del>62 Nevada Road</del> , Hamilton (NZ). WOODWARD, Vaughan, Grant [NZ/NZ]; 3 Fox Street, Hamilton (NZ). OGLE, Colin, Roger [NZ/NZ]; 3 David Street, Nawton (NZ).			
(74) Agents: CALHOUN, Douglas, C. et al.; A. J. Park & Son, Huddart Parker Building, 6th floor, Post Office Square, P.O. Box 949, Wellington 6015 (NZ).		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	



(54) Title: BIODEGRADABLE INTRA VAGINAL DEVICES



## (57) Abstract

An intra vaginal device for delivering a pharmaceutical agent (e.g. progesterone) into a recipient mammal. The active agent is carried in a matrix of a biodegradable polymer (such as poly  $\epsilon$ -caprolactone or a starch-like polysaccharide) having an ability to provide (without reliance on a supporting spine) desired retention characteristics of a variable geometry retention device, an appropriate release profile during a finite insertion period and biodegradability upon removal from the mammal.

## ABSTRACT

An intra vaginal device for a target species mammal. It has or is moulded mass of at least primarily one or both or poly  $\epsilon$ -caprolactone and a mouldable biodegradable starch-like polysaccharide. The mass includes a pharmaceutical agent(eg. Progesterone)  
5 to be administered by the intra vaginal route.

The mass is able to deliver the agent during a retention period of time without substantial degradation of the integrity of the mass yet the mass, upon withdrawal and over time, will degrade if left in the open. Despite the mass, the device as a whole is (i) retainable by being resiliently conformable to allow insertion prior to recovery to a  
10 geometry to minimise spontaneous rejection from the vagina in the target species mammal, and (ii) recoverable by a simple pulled withdrawal after said retention period with said mass substantially intact.



## BIODEGRADABLE INTRA VAGINAL DEVICES

The present invention relates to improvements in and/or relating to intra vaginal devices or inserts.

5 Our PCT/NZ97/00052 (published as WO 97/40776) discloses a variety of different forms of intra vaginal device of a variable geometry type for retention within the intra vaginal cavity of an animal. Such devices hitherto have primarily involved the use of a silicone rubber composition which as a matrix has been impregnated with the active pharmaceutical agent (eg; progesterone). In the variable geometry type devices typified  
10 by the CIDR™ devices of this company the impregnated matrix has primarily been supported on a spine of a resilient material such as nylon, the resilience of which is utilised for the variable geometry retention characteristics notwithstanding that such spine is usually fully overlaid with the impregnated matrix.

Various polymers possessing the ability to undergo biodegradation have been used  
15 to deliver pharmaceutical agents. A class of polymers possessing this characteristic and extensively utilized for the delivery of pharmaceutical agents are the polyesters. Examples of these polymers include poly lactic acid, poly glycolic acid, poly ( $\epsilon$ -caprolactone) and various co-polymers of lactide, glycolide and  $\epsilon$ -caprolactone.

Pharmaceutical products utilizing these polymers are typically formulated as  
20 microspheres, microcapsules, films, rods or blocks. Retention within a body cavity has been achieved by a number of methods; the addition of dense fillers, injections or surgical implantation into muscle or subcutaneous area.

The present invention relates to a device or insert designed to deliver progesterone over an extended period of time (2 to 20 days) upon insertion into the vagina of animals  
25 such as cattle, sheep, horses, pigs, goats, buffalo or deer. The device or insert is retained within the vagina by means of a flexible geometric arrangement (eg; of the arms and body).

Upon completion of treatment the device is removed and disposed of in a manner that preferably capitalizes upon the biodegradable properties of the polymer.

30 We have determined that biodegradable polymers typified by poly( $\epsilon$ -caprolactone) or a starch like saccharide can be appropriately impregnated with an intra vaginally



effective active agent [such as progesterone (e.g. in concentration of from 5% to 70% w/w)] so as to provide appropriate *in vivo* release characteristics for the active agent over a period of intra vaginal retention required by the particular procedure whereupon, after extraction, the material is readily biodegradable following removal from the  
5 animal.

Surprisingly it has also been found that a polymer such as a poly ( $\epsilon$ -caprolactone) can be moulded notwithstanding its being impregnated with the active agent to provide not only the impregnated matrix but also to provide the variable geometry device without an obligatory presence of a spine or the like such as in the prior art devices.  
10 Similarly, starch like saccharides have been found to be capable of being shaped to the same effect.

Accordingly in a first aspect the present invention consists in **an intra vaginal device or insert** for a target species mammal and of a kind capable of intra vaginal insertion, intra vaginal retention for a period of time and removal from the vagina by  
15 a simple pulled withdrawal **characterised in that**

- (i) said device or insert has or is a moulded mass of at least primarily one or both of poly ( $\epsilon$ -caprolactone) and a mouldable biodegradable starch-like polysaccharide,
- (ii) said mass includes a pharmaceutical agent to be administered into the  
20 target species mammal by the intra vaginal route,
- (iii) said mass delivers said pharmaceutical agent intra vaginally during said retention period of time without substantial degradation of the integrity of the mass yet said mass, upon withdrawal and, over time, will degrade if left in the open, and
- (iv) despite said mass, the device or insert as a whole is intra vaginally  
25 retainable by being resiliently conformable to allow insertion and thereafter to recover to a geometry to minimise spontaneous rejection from the vagina.

Preferably the device or insert is vaginally retainable for at least 2 days in a target species mammal.

Preferably the agent is progesterone.



Preferably the progesterone comprises from 5 to 70% w/w.

Preferably the polymer is or includes poly ( $\epsilon$ -caprolactone), or alternatively the polymer is or includes a starch-like polysaccharide.

Preferably said mass includes therein cyclodextrin.

5 Preferably the cyclodextrin(s) comprise from 5 to 70% w/w of said mass.

Preferably said agent does not appear as a fine powder or crystals upon the surface of said mass.

Preferably said device or insert comprises or includes the said mass which defines at least substantially all of said device or insert.

10 In another aspect the present invention is **an intra vaginal device or insert** for a target species mammal comprising or including an intra vaginally insertable, retainable and removable mass of at least primarily one or both of poly ( $\epsilon$ -caprolactone) and a mouldable biodegradable starch-like polysaccharide, the mass by virtue of its resilience being of variable geometry which allows the intra vaginal insertion, retention and  
15 removal,

wherein said mass includes therein sufficient progesterone therein such that for a target species a blood serum level of progesterone of greater than  $2^{ng}/_{ml}$  for a period of at least 5 days can follow intra vaginal insertion thereof and wherein after removal the mass is biodegradable after removal from the animal.

20 Preferably said target species is selected from cattle, sheep, horses, pigs, goats, buffalo and deer.

Preferably said device or insert includes no supporting spine (eg; nylon or polyester).

25 Preferably the progesterone inclusion is sufficient to deliver progesterone for a period from 2 to 20 days.

Optionally said mass may include cyclodextrin.

In a further aspect the present invention consists in **the use or method of use** of such a device or any device of the present invention.

The present invention also consists in **a method of manufacture of an intra vaginal device** which results in any device in accordance with the present invention.

In another aspect the invention consists in **a method of manufacture of an intra**



**vaginal device** which comprises the step of including in a mouldable biodegradable polymer matrix both a cyclodextrin and an intra vaginally effective agent.

In still another aspect the invention consists in **the use inter alia for animal group oestrus synchrony purposes** of devices or inserts of the present invention.

5 Preferably said use is intra vaginal use for a period of from 2 to 20 days and said device has a capability in the target species mammal of providing for at least 5 days (if intra vaginally inserted for at least about 5 days) a blood serum level of progesterone of greater than  $2^{ng}/_{ml}$ .

10 Preferably all polymer(s) of the said mass (if all, as is preferred, is to moulded) can be moulded without use of conditions prejudicial to the pharmaceutical agent and any cyclodextrin (or for that matter, any other absorption enhancing agent) present.

In still a further aspect the invention consists in **a method of achieving with an animal (or group of animals) a blood serum level of progesterone of greater than  $2^{ng}/_{ml}$  for a period of at least 5 days**, said method comprising inserting and retaining  
15 in the or each animal for at least the at least 5 day period a device or insert of the present invention.

We have found that the biodegradable polymers of choice are capable of being effectively impregnated with the pharmaceutical agent and optionally an absorption enhancement agent, being effectively moulded into the form of an intra vaginal device  
20 or insert of a kind reliant on variable geometry for retention, providing over the finite insertion period an appropriate tract to provide a desired pharmacological effect without detriment from any propensity of the polymer(s) to *in vivo* biodegrade, and, upon removal much lower in pharmaceutical agent content (see WO 97/40776), of providing no long term disposal problem owing to the propensity of the polymer(s) to biodegrade  
25 after removal from the animal.

Preferred forms of the present invention will now be described with reference to the accompanying drawings in which:

Figure 1 shows a device of variable geometry (the geometry being variable much in the way as discussed in WO 97/40776) but without a need for a spine of a dissimilar material (although if desired that can optionally be present).

Figure 2 shows an *in vitro* cumulative progesterone release against the square-



root-of-time (inserts manufactured from poly ( $\epsilon$ -caprolactone) (thin line) or silicone (thick line)).

Figure 3 shows an average plasma progesterone concentration against time following two rounds of vaginal treatment with a silicone insert of 134 cm<sup>2</sup> surface area (□) or a poly ( $\epsilon$ -caprolactone) insert of 105 cm<sup>2</sup> surface area (■), both of which contain 10% w/w progesterone (error bars are standard error means (n=12 for silicone inserts, n=9 for poly ( $\epsilon$ -caprolactone) inserts)),


Figure 4 shows a percentage of initial mass lost for drug-loaded (■) and blank (□) poly ( $\epsilon$ -caprolactone) inserts stored in compost over time (the solid line is the suggested mass loss as per promotional literature supplied by the poly ( $\epsilon$ -caprolactone) manufacturer (error bars are ranges (n=2)),

Figure 5 shows a percentage of tensile performance lost for drug-loaded (■) and blank (□) poly ( $\epsilon$ -caprolactone) inserts buried in compost over time (the solid line is the suggested tensile performance loss as per promotional literature supplied by the manufacturer. (Error bars are ranges (n=2)),

Figure 6 shows plasma progesterone concentration against time following vaginal treatment for 7 days with a silicone insert of 134 cm<sup>2</sup> surface area (■), poly ( $\epsilon$ -caprolactone) insert of 115 cm<sup>2</sup> surface area (□) or poly ( $\epsilon$ -caprolactone) with lactose insert of 115 cm<sup>2</sup> surface area (○) (A final plasma sample was collected 6 hours after removal on day 7. (Error bars are standard error means (n=3)),

Figure 7 shows the percentage of initial mass lost for various poly ( $\epsilon$ -caprolactone) formulations stored in compost over time [Poly ( $\epsilon$ -caprolactone) (◆), poly ( $\epsilon$ -caprolactone) with 10% w/w progesterone (■), poly ( $\epsilon$ -caprolactone) with 12.1% w/w lactose and 10.47% w/w progesterone (▲), poly ( $\epsilon$ -caprolactone) with 37.2% w/w  $\beta$ -cyclodextrin and 10.3% w/w progesterone (x), poly ( $\epsilon$ -caprolactone) with 43.8% w/w hydroxypropyl  $\beta$ -cyclodextrin and 10% w/w progesterone (\*) or poly ( $\epsilon$ -caprolactone) with 39.9% w/w  $\gamma$ -cyclodextrin and 9.7% w/w progesterone (●). (Error bars are ranges (n=2))], and

Figure 8 shows plasma progesterone concentration against time following vaginal treatment for 7 days with a Mater-Bi insert of 58 cm<sup>2</sup> surface area with (■) or without (●) the addition of 20% w/w NaCl. (Error bars are ranges (n=2)).



The choice of a resilient mouldable or shapable "polymer" which is biodegradable is such that degradation of the impregnated matrix (but with a low residual active ingredient loading) will occur over time after removal from the animal after having served its purpose during an intra vaginal insertion of preferably from 2 to 20 days (eg; 5 about 7 days). Minimal degradation (if any) occurs during the period of insertion.

In the device of Figure 1 the device is wholly of the impregnated matrix which is poly ( $\epsilon$ -caprolactone) impregnated with progesterone in the concentration of 5 to 70% w/w without any solid active pharmaceutical agent appearing as a fine powder or crystals on the surface of the device.

10 In Figure 1 the wings 1 are resilient with respect to the body 2 and in an intra vaginal injection mode can be reduced to a form or assume a position in an applicator in a known manner which facilitates insertion after which the resilience deploys the wings 1 to such condition as is required for retention. The resilience can be subsequently utilised to withdraw the device from within the vagina.

15 A suitable source of poly ( $\epsilon$ -caprolactone) is that product TONE 767<sup>TM</sup> from Union Carbide Specialty Polymers and Products, Danbury, Ct. USA.

Starch-like polysaccharides that can likewise be impregnated and can be used for some or all of the device include MATER-Bi<sup>TM</sup> available from Novamont, Italy.

A preferred method of manufacturing of the device is as follows: Polymer poly 20  $\epsilon$ -caprolactone, starch-like polysaccharide or a blend of the two are mixed with active into a mixing vat using a suitable compound, eg; surfactant to adhere the active to the surface of the polymer granules or the use of compound extruded material.. The polymer/active mixture is then loaded into the hopper of an injection moulding machine, and processed as a conventional thermoplastic, with machine set point 25 parameters as per the technical recommendations of the polymer suppliers literature, and as per injection moulding standard practice.

Key processing set points for poly  $\epsilon$ -caprolactone are: barrel temperatures ranging from 80 - 120°C with an injection pressure of 1600 bar. Total cycle time due to long cooling phase of approximately 55 seconds. Product is removed from the die and allowed to cool to equilibrium prior to packaging.

Preferably the performance of the device while inserted and its effect upon



withdrawal is substantially as discussed in WO 97/40776 but with the advantages of (i) biodegradability after removal from the animal and (ii) the preferred omission of a spine of resilient material.

5 The preferred biodegradable polymers (typified by poly ( $\epsilon$ -caprolactone) or a starch like saccharide) can be appropriately impregnated with an intra vaginally effective active agent such as progesterone (eg: in concentration of from 5% to 70% w/w) and an absorption enhancing agent such as hydroxypropyl  $\beta$ -cyclodextrin (eg: in concentrations of from 5% to 70% w/w) so as to provide appropriate release characteristics for the active agent over the period of intra vaginal retention.

10 The preferred device is wholly of the impregnated matrix which is poly ( $\epsilon$ -caprolactone) impregnated with hydroxypropyl  $\beta$ -cyclodextrin in the concentration of 5 to 70% w/w.

A suitable source of hydroxypropyl  $\beta$ -cyclodextrin is that product BETA W7 HP available from Wacker Chemicals Australia, Victoria, Australia.

15 A preferred method of manufacture of the device is as follows: Polymer (poly ( $\epsilon$ -caprolactone), starch-like polysaccharide or a blend of the two) are mixed with active and absorption agent into a mixing vat. The polymer/active/absorption agent mixture is then loaded into the hopper of an injection moulding machine; and processed as a conventional thermoplastic, with machine set point parameters as per technical  
20 recommendations of the polymers suppliers literature, and as per injection moulding standard practice. Key processing points are: barrel temperatures ranging from 60 - 250°C with an injection pressure of 1600 bar. Total cycle time due and allowed to cool to equilibrium prior to packaging.

Figure 1 shows a device of variable geometry (the geometry being variable much  
25 in the way as discussed in WO 97/40776) but without a need for a spine of a dissimilar material (although if desired that can optionally be present),

When inserts of the type shown in Figure 1 manufactured from poly ( $\epsilon$ -caprolactone) are subjected to an *in vitro* dissolution procedure to assess the release of progesterone they display release characteristics similar to the silicone CIDR-B™  
30 insert, Figure 2.

Figure 2 shows an *in vitro* cumulative progesterone release against the square-



root-of-time. Inserts manufactured from poly ( $\epsilon$ -caprolactone) (thin line) or silicone (thick line).

When inserts of the type shown in Figure 1 manufactured from poly ( $\epsilon$ -caprolactone) of surface area less than the silicone CIDR-B™ inserts are administered to cattle and plasma samples collected for plasma progesterone concentration analysis slightly lower levels are observed, Figure 3.

Figure 3 shows an average plasma progesterone concentration against time following two rounds of vaginal treatment with a silicone insert of 134 cm<sup>2</sup> surface area ( $\square$ ) or a poly ( $\epsilon$ -caprolactone) insert of 105 cm<sup>2</sup> surface area ( $\blacksquare$ ), both of which contain 10% w/w progesterone. Error bars are standard error means (n=12 for silicone inserts, n=9 for poly ( $\epsilon$ -caprolactone) inserts).

When inserts of the type depicted in Figure 1 manufactured from poly ( $\epsilon$ -caprolactone) which contain progesterone at 10 % w/w or no progesterone are stored in compost for a period of 6 months the following mass losses are observed, Figure 4.

Figure 4 shows a percentage of initial mass lost for drug-loaded ( $\blacksquare$ ) and blank ( $\square$ ) poly ( $\epsilon$ -caprolactone) inserts stored in compost over time. The solid line is the suggested mass loss as per promotional literature supplied by the poly ( $\epsilon$ -caprolactone) manufacturer. Error bars are ranges (n=2).

When inserts of the type depicted in Figure 1 manufactured from poly ( $\epsilon$ -caprolactone) which contain progesterone at 10 % w/w or no progesterone are stored in compost for a period of 6 months the following tensile performance losses are observed, Figure 5.

Figure 5 shows a percentage of tensile performance lost for drug-loaded ( $\blacksquare$ ) and blank( $\square$ ) poly ( $\epsilon$ -caprolactone) inserts buried in compost over time. The solid line is the suggested tensile performance loss as per promotional literature supplied by the manufacturer. Error bars are ranges (n=2).

When inserts of the type shown in Figure 1 manufactured from poly ( $\epsilon$ -caprolactone) of surface area similar to our silicone CIDR-B™ insert (disclosed in aforementioned WO 97/40776) are administered to cattle and plasma samples collected from plasma progesterone concentration analysis similar levels are observed. See Figure 6.





Figure 6 shows plasma progesterone concentration against time following vaginal treatment for 7 days with a silicone insert of 134 cm<sup>2</sup> surface area (■), poly (ε-caprolactone) insert of 115 cm<sup>2</sup> surface area (□) or poly (ε-caprolactone) with lactose insert of 115 cm<sup>2</sup> surface area (○). A final plasma sample was collected 6 hours after removal on day 7. Error bars are standard error means (n=3).

When inserts of the type depicted in Figure 1 manufactured from poly (ε-caprolactone) which contain various excipients are stored in compost for a period of 6 months the mass losses shown in Figure 7 are observed.

Figure 7 shows the percentage of initial mass lost for various poly (ε-caprolactone) formulations stored in compost over time. Poly (ε-caprolactone) (◆), poly (ε-caprolactone) with 10% w/w progesterone (■), poly (ε-caprolactone) with 12.1% w/w lactose and 10.47% w/w progesterone (▲), poly (ε-caprolactone) with 37.2% w/w β-cyclodextrin and 10.3% w/w progesterone (x), poly (ε-caprolactone) with 43.8% w/w hydroxypropyl β-cyclodextrin and 10% w/w progesterone (\*) or poly (ε-caprolactone) with 39.9% w/w γ-cyclodextrin and 9.7% w/w progesterone (●). Error bars are ranges (n=2).

When inserts are the type shown in Figure 1 manufactured using polysaccharide are administered to cattle and plasma samples collected for plasma progesterone concentration analysis the levels of Figure 8 are observed.

Figure 8 shows plasma progesterone concentration against time following vaginal treatment for 7 days with a Mater-Bi insert of 58 cm<sup>2</sup> surface area with (■) or without (●) the addition of 20% w/w NaCl. Error bars are ranges (n=2).



**WHAT WE CLAIM IS:**

1. **An intra vaginal device or insert** for a target species mammal and of a kind capable of intra vaginal insertion, intra vaginal retention for a period of time and removal from the vagina by a simple pulled withdrawal **characterised in that**

- (i) said device or insert is a moulded mass of at least primarily one or both of poly ( $\epsilon$ -caprolactone) and a mouldable biodegradable starch-like polysaccharide,
- (ii) said mass includes a pharmaceutical agent to be administered into the target species mammal by the intra vaginal route,
- (iii) said mass delivers said pharmaceutical agent intra vaginally during said retention period of time without substantial degradation of the integrity of the mass yet said mass, upon withdrawal and, over time, will degrade if left in the open, and
- (iv) despite said mass, the device or insert as a whole is intra vaginally retainable by being resiliently conformable to allow insertion and thereafter to recover to a geometry to minimise spontaneous rejection from the vagina.

2. A device or insert of claim 1 which is vaginally retainable for at least 2 days in a target species mammal.

3. A device or insert of claim 1 or 2 wherein the agent is progesterone.



4. A device or insert of claim 3 wherein the progesterone comprises from 5 to 70% w/w.

5. A device or insert of claim 1 wherein the polymer is or includes poly ( $\epsilon$ -caprolactone).

7. A device or insert of claim 1 wherein the polymer is or includes a starch-like polysaccharide.

8. A device or insert of any one of claims 1 to 7 wherein said mass includes therein cyclodextrin.

9. A device or insert of claim 8 wherein the cyclodextrin(s) comprise from 5 to 70% w/w of said mass.



10. A device or insert of any one of the preceding claims wherein the agent does not appear as a fine powder or crystals upon the surface of said mass.

11. A device or insert of any one of the preceding claims wherein said mass defines at least substantially all of said device or insert.

12. **An intra vaginal device or insert** for a target species mammal being primarily an intra vaginally insertable, retainable and removable mass of at least primarily one or both of poly ( $\epsilon$ -caprolactone) and a mouldable biodegradable starch-like polysaccharide, the mass by virtue of its resilience being of variable geometry which allows the intra vaginal insertion, retention and removal,

wherein said mass includes therein sufficient progesterone therein such that for a target species a blood serum level of progesterone of greater than  $2^{\text{ng/ml}}$  for a period of at least 5 days can follow intra vaginal insertion thereof and wherein after removal the mass is *in vitro* biodegradable.

13. A device or insert of claim 12 wherein said target species is selected from cattle, sheep, horses, pigs, goats, buffalo and deer.

14. A device or insert of claim 12 or 13 absent of any supporting spine.

15. A device or insert of any one of claims 12 to 14 wherein the progesterone inclusion is sufficient to deliver progesterone for a period from 2 to 20 days.


16. A device or insert of any one of claims 12 to 15 wherein said mass may include cyclodextrin.

17. **The use for target mammal species group oestrus synchrony purposes of devices or inserts of any one of claims 1 to 16.**



18. A use of claim 20 wherein said use is intra vaginal use for a period of from 2 to 20 days and said device has a capability in the target species mammal of providing for at least 5 days (if intra vaginally inserted for at least about 5 days) a blood serum level of progesterone of greater than  $2^{\text{ng/ml}}$ .


19. **A method of achieving with an animal (or group of animals) a blood serum level of progesterone of greater than  $2^{\text{ng/ml}}$  for a period of at least 5 days, said method comprising inserting and retaining in the or each animal for at least the at least 5 day period a device or insert of any one of claims 1 to 16.**









**FIGURE 1**

**FIGURE 2****FIGURE 3**

**FIGURE 4**

**FIGURE 5****FIGURE 6**

**FIGURE 7**

**FIGURE 8**